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Abstract
IMPORTANCE Patients with transient ischemic attack (TIA) are at high risk of recurrent vascular
events. Timely management can reduce that risk by 70%; however, gaps in TIA quality of care exist.
OBJECTIVE To assess the performance of the Protocol-Guided Rapid Evaluation of Veterans
Experiencing New Transient Neurological Symptoms (PREVENT) intervention to improve TIA quality
of care.
DESIGN, SETTING, AND PARTICIPANTS This nonrandomized cluster trial with matched controls
evaluated a multicomponent intervention to improve TIA quality of care at 6 diverse medical centers
in 6 geographically diverse states in the US and assessed change over time in quality of care among
36 matched control sites (6 control sites matched to each PREVENT site on TIA patient volume,
facility complexity, and quality of care). The study period (defined as the data period) started on
August 21, 2015, and extended to May 12, 2019, including 1-year baseline and active implementation
periods for each site. The intervention targeted clinical teams caring for patients with TIA.
INTERVENTION The quality improvement (QI) intervention included the following 5 components:
clinical programs, data feedback, professional education, electronic health record tools, and
QI support.
MAIN OUTCOMES AND MEASURES The primary outcome was the without-fail rate, which was
calculated as the proportion of veterans with TIA at a specific facility who received all 7 guideline-
recommended processes of care for which they were eligible (ie, anticoagulation for atrial fibrillation,
antithrombotic use, brain imaging, carotid artery imaging, high- or moderate-potency statin therapy,
hypertension control, and neurological consultation). Generalized mixed-effects models with
multilevel hierarchical random effects were constructed to evaluate the intervention associations
with the change in the mean without-fail rate from the 1-year baseline period to the 1-year
intervention period.
RESULTS Six facilities implemented the PREVENT QI intervention, and 36 facilities were identified
as matched control sites. The mean (SD) age of patients at baseline was 69.85 (11.19) years at
PREVENT sites and 71.66 (11.29) years at matched control sites. Most patients were male (95.1% [154
of 162] at PREVENT sites and 94.6% [920 of 973] at matched control sites at baseline). Among the
PREVENT sites, the mean without-fail rate improved substantially from 36.7% (58 of 158 patients) at
baseline to 54.0% (95 of 176 patients) during a 1-year implementation period (adjusted odds ratio,
2.10; 95% CI, 1.27-3.48; P = .004). Comparing the change in quality at the PREVENT sites with the
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Key Points
Question Is the Protocol-Guided Rapid
Evaluation of Veterans Experiencing
New Transient Neurological Symptoms
(PREVENT) program associated with
improved care for transient
ischemic attack?
Findings This nonrandomized cluster
trial with matched controls (including 6
PREVENT sites and 36 matched control
sites) evaluated quality of care for
transient ischemic attach across 7
guideline-recommended processes of
care measured by the without-fail rate.
Over the course of a 1-year
implementation period, the mean
without-fail rate improved 17% at the 6
PREVENT sites and only 3% at 36
matched control sites.
Meaning These findings suggest that
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Abstract (continued)
matched control sites, the improvement in the mean without-fail rate was greater at the PREVENT
sites than at the matched control sites (36.7% [58 of 158 patients] to 54.0% [95 of 176 patients]
[17.3% absolute improvement] vs 38.6% [345 of 893 patients] to 41.8% [363 of 869 patients] [3.2%
absolute improvement], respectively; absolute difference, 14%; P = .008).
CONCLUSIONS AND RELEVANCE The implementation of this multifaceted program was associated
with improved TIA quality of care across the participating sites. The PREVENT QI program is an
example of a health care system using QI strategies to improve performance, and may serve as a
model for other health systems seeking to provide better care.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02769338
JAMA Network Open. 2020;3(9):e2015920. doi:10.1001/jamanetworkopen.2020.15920
Introduction
Approximately 8500 veterans with transient ischemic attack (TIA) or ischemic stroke are cared for in
Department of Veterans Affairs (VA) emergency departments (EDs) or inpatient wards annually in
the United States.1 Patients with TIA generally present with transient neurological symptoms of a
presumed ischemic cause.2 Patients with TIA are at a high risk of recurrent vascular events3-5;
however, delivery of timely TIA care can reduce that risk by up to 70%.6-9 Despite the known
benefits of timely TIA care, gaps in TIA quality of care exist in both private-sector US hospitals10 and
VA facilities.11,12
In a learning health care system, “clinical informatics, incentives, and culture are aligned to
promote continuous improvement and innovation, with best practices seamlessly embedded in the
delivery process and new knowledge captured as an integral by-product of the delivery
experience.”13(p136) Within a learning health care system, health care teams respond to quality
problems by using quality improvement (QI) strategies and systems redesign approaches to improve
performance, depending on the complexity and scope of the problem.14 The objective of the
Protocol-Guided Rapid Evaluation of Veterans Experiencing New Transient Neurological Symptoms
(PREVENT) trial was to evaluate a multicomponent QI intervention to improve the quality of TIA
care.15 The PREVENT intervention was designed to align with the learning health care
system model.13,15
Methods
This nonrandomized cluster trial with matched controls16,17 included 6 participating sites (referred to
as PREVENT sites), where active implementation was initiated in 3 waves, with 2 facilities per wave
(Figure 1), and 36 matched control sites (Trial protocol in Supplement 1). The cluster design
permitted the dissemination of intervention resources to all intervention teams over time seeking to
fundamentally improve the standard of care for all patients with TIA at participating sites.16,17 The
intervention was at the facility level, but the unit of analysis was at the patient level. This study
followed the Standards for Reporting Implementation Studies (StaRI) Statement. The study received
human participant approval from the Indiana University School of Medicine Institutional Review
Board and the Richard L. Roudebush VA Medical Center Research and Development Committee. A
waiver of written informed consent was granted by the institutional review board for the collection of
medical record data because the data were obtained retrospectively from administrative sources.
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Setting and Study Periods
Within the VA, quality measurement and systems redesign are integrated into the health care system
within administrative and clinical operations.18,19 Although stroke care quality metrics are reported
herein, there is no VA systemwide focus on TIA quality of care.
The site recruitment methods have been described.15 The VA hospitals were rank ordered in
terms of quality of TIA care12; invitations to participate were sent beginning with facilities with the
lowest performance and the highest TIA annual patient volume. Recruitment continued until 6
facilities agreed to participate. These 6 sites were in 6 geographically diverse states in the US. The
PREVENT sites were pragmatically allocated to waves based on the ability to schedule baseline
meetings.
Six control sites were matched to each of the 6 PREVENT sites based on TIA patient volume,
facility complexity (ie, teaching status, intensive care unit level), and quality of care (measured by the
without-fail rate, described below). The total number of matched control sites was 36.
The baseline period extended for 12 months before the baseline site visit at the participating
facilities (Figure 1). The active implementation period began 1 month after the kickoff (Figure 1),
which was the day that the site launched the program, providing 1 month for facility teams to initiate
QI activities before assessment of outcomes began. The kickoffs were scheduled in waves, with 2
Figure 1. Study Flow Diagram
130 Facilities screened for eligibility
105 Potentially eligible facilities
34 Facilities invited to participate
2 Facilities wave 1
Intervention kickoffs (July 2017)
2 Facilities wave 2 2 Facilities wave 3
6 Facilities agreed to participate (PREVENT quality improvement sites)
25 Facilities excluded
24 Fewer than 10 patients with TIA per year
1 Site serving as coordinating center
36 Matched control sites
6 Control sites for each PREVENT
implementation site;
baseline and implementation
periods for the control sites
were identical to the dates
used to define the periods for
the PREVENT implementation sites
28 Facilities declined to participate
Baseline period
43 Patients (August 2015
to August 2016)
Implementation period
31 Patients (August 2017
to August 2018)
Intervention kickoffs
(October 2017 to November 2017)
Baseline period
70 Patients (June 2016
to July 2017)
Implementation period
58 Patients (November 2017
to December 2018)
Intervention kickoffs
(December 2017 to April 2018)
Baseline period
49 Patients (August 2016
to January 2018)
Implementation period
100 Patients (January 2018
to May 2019)
0 Facilities discontinued the intervention
162 Patients were included in the 1-y baseline period
189 Patients were included in the 1-y intervention period
158 Baseline patients were eligible for ≥1 process of care and were included in the quality-of-care analyses
176 Intervention patients were eligible for ≥1 process of care and were included in the quality-of-care analyses
Invitations sent in order from high to low volume,
recruitment continued until 6 sites enrolled
Shown is the nonrandomized cluster trial with matched controls study design, with 2 facilities per wave and 6 matched control sites for every PREVENT (Protocol-Guided Rapid
Evaluation of Veterans Experiencing New Transient Neurological Symptoms) site. TIA indicates transient ischemic attack.
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sites per wave; the first kickoff was on July 11, 2017, and the last one was on April 13, 2018. Therefore,
the baseline and implementation periods were temporally staggered across the waves. The time
between the baseline visit and the kickoff varied, depending on the availability of site team members
to schedule the full-day kickoff. The period between the baseline visit and the kickoff was excluded
from the analyses. The first baseline period (wave 1, site 1) began on August 21, 2015, and the last
baseline period (wave 3, site 2) ended on January 30, 2018. The first implementation period began
on August 11, 2017, and the final implementation period ended on May 12, 2019. The definition of the
baseline period (specific start and end dates of the 1-year baseline period) for each matched control
site was identical to the definition used for the PREVENT site to which the controls were matched.
QI Intervention
The rationale and methods used to develop the PREVENT intervention have been described.15 The
PREVENT intervention was designed on the basis of an assessment of TIA care performance at VA
facilities nationwide, as well as an evaluation of barriers to and facilitators of TIA care performance
using the following 4 information sources: baseline quality-of-care data,12 staff interviews,20 existing
literature,21-24 and validated electronic quality measures.12,25
The PREVENT QI intervention targeted facility staff rather than patients. External facilitation
was provided by the study team (D.M.B., L.J.M., E.J.M., N.A.R., and T.M.D.), primarily by a nurse with
quality management expertise and secondarily by a physician (D.M.B.) with both cerebrovascular
disease content knowledge and systems redesign experience. The rest of the study team members
had complementary experience in implementation science, data science, and systems redesign. The
composition of the participating facility teams varied across sites but generally included neurologists,
emergency medicine practitioners, nurses, pharmacists, and radiologists; some teams also included
hospitalists, clinicians, education staff, telehealth staff, and systems redesign staff.
The PREVENT intervention targeted clinical teams (not patients) and consisted of the following
5 components: clinical programs (including clinical pathways with educational materials and
documentation tools), data feedback, professional education, electronic health record tools, and QI
support (including a virtual collaborative).15 Active implementation of the PREVENT intervention
involved a full-day kickoff during which the facility team explored their site-specific quality of care
data to identify processes of care with the largest gaps in quality for the greatest number of patients.
Using systems redesign approaches, facility team members brainstormed about barriers to providing
the highest quality of care, identified solutions to address barriers, ranked solutions in terms of
potential benefits and effort, and developed a site-specific action plan. Local QI plans were entered
into the PREVENT web-based hub, and quality metrics were tracked, allowing teams to monitor
performance over time. During the 1-year active implementation period, site teams joined monthly
virtual collaborative conferences, a forum for cross-site conversation and discussion, including
sharing progress on action plans, articulating goals for the next month, and reviewing any new
evidence or tools. The design of the PREVENT QI program advanced the following 3 aspects of a
learning health care system: learning from data (via the PREVENT hub, which unlike static
performance dashboards allowed teams to examine and interact with their performance data to
explore hypotheses, plan QI activities, and evaluate change over time), learning from each other (via
the virtual collaborative conferences), and sharing best practices (via the growing library of diverse
resources on the PREVENT hub).15
Outcomes
The primary outcome was the without-fail rate (sometimes referred to as defect-free care26,27),
which is an all-or-none measure of quality of care.28 The without-fail rate is calculated as the
proportion of veterans with TIA at a specific facility who received all of the processes of care for
which they were eligible from among the following 7 guideline-recommended processes of care:
anticoagulation for atrial fibrillation within 7 days of discharge, antithrombotic use within 2 days after
the event, brain imaging within 2 days after the event or 1 day before the index TIA, carotid artery
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imaging within 2 days after the event or 6 months before the event, high- or moderate-potency
statin therapy within 7 days of discharge, hypertension control over the 90 days after discharge, and
neurological consultation by day 1 after the TIA.15,25 The processes of care were based on electronic
health record data using validated algorithms.12,25 The without-fail rate was based on guideline-
recommended processes of care6,29 and has been associated with improved outcomes.30 Given the
all-or-none nature of the without-fail rate, it can be a difficult outcome to change, and even small
improvements in the absolute rate may reflect substantial changes in practice at the facility level.28
The prespecified secondary outcomes were the consolidated measure of quality (number of
passes divided by number of opportunities) and the individual processes of care that were included
in both the without-fail rate and the consolidated measure of quality. eTable 1 in Supplement 2 lists
the numerator and denominator definitions for each process of care.
We also examined the 90-day recurrent stroke rate, 90-day recurrent vascular event rate, and
90-day mortality rate (eTable 2 in Supplement 2 lists the diagnosis codes).7,8,24 Recurrent stroke
(defined as an ischemic stroke in the emergency department [ED] or resulting in an inpatient
admission within 90 days of discharge of the index TIA event) and recurrent vascular events31
(defined as an ED visit or inpatient admission within 90 days of discharge for congestive heart failure,
myocardial infarction or acute coronary syndrome, ischemic stroke, TIA, ventricular arrhythmia, or
death) were identified via primary diagnosis codes in the ED or inpatient setting using a combination
of both VA and fee-basis data (which describe health care in non–VA facilities that was paid for by the
VA). Therefore, recurrent stroke or recurrent vascular events that occurred in community hospitals
but were not paid for by the VA were not included. The 90-day all-cause mortality rate (defined as
death from any cause within 90 days of presentation for the index event) was obtained from the VA
Vital Status File.32
Identification of Patients With TIA for Calculation of the Quality Measures
Details of our methods have been described.15 We retrospectively identified veterans with TIA who
were cared for in the ED or inpatient setting based on primary discharge codes for TIA (International
Classification of Diseases, Ninth Revision [ICD-9] 435.x, excluding 435.2; and International Statistical
Classification of Diseases and Related Health Problems, Tenth Revision [ICD-10] codes G45.0, G45.1,
G45.8, G45.9, and I67.848).25 Patients with possible TIA events who were cared for entirely in the
outpatient setting (without either an ED visit or inpatient admission) were not included. Comparing
this electronic health record approach with chart review, 95.0% (436 of 459) of the patients
classified as having a TIA using the electronic health record approach were found to have a TIA
diagnosis in the chart review, 4.1% (19 of 459) of cases had a chart review diagnosis of ischemic
stroke, and 0.9% (4 of 459) of patients had another diagnosis (neither stroke nor TIA).25 Patients
cared for in hospital observation settings were classified as inpatients. Patients cared for in an ED
without an inpatient or observation unit admission were classified as ED-only patients.
Data Sources
Process of care data were obtained from the VA Corporate Data Warehouse (CDW), which includes a
broad range of information from the VA electronic medical record system, known as Veterans
Information Systems and Technology Architecture (VistA). VistA is the electronic medical record
system that is used across the entire VA system nationwide and includes clinical and administrative
functionality.33 The CDW data included inpatient and outpatient data files (eg, clinical encounters
with associated diagnostic and procedure codes) in the 5 years before the event to identify medical
history,34 health care use, and receipt of procedures (Current Procedural Terminology, Healthcare
Common Procedures Coding System, and ICD-9 and ICD-10 procedure codes). The CDW data were
also used for vital signs, laboratory data, allergies, imaging, orders, medications, and clinical
consultations. Most CDW data are updated nightly. Fee-basis data were also used to identify
inpatient and outpatient health care use and medical history.
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Statistical Analysis
The Fisher exact test was used to compare whether categorical variables differed between the
PREVENT sites and the matched control sites as well as between baseline and implementation
periods. Two-sample t tests or Wilcoxon rank sum tests were used to ascertain whether continuous
outcomes differed between the PREVENT sites and the matched control sites as well as between
baseline and implementation periods. Generalized mixed-effects models at the patient level, with
random effects for site and fixed effects for wave, were used to analyze the PREVENT intervention
associations.35 Separate risk-adjustment models were constructed for each process of care, for the
without-fail rate, and for the consolidated measure of quality. Fully risk-adjusted models included
site, wave, and the specific patient characteristics that were associated with the particular outcome
of interest (eg, the without-fail rate). Variables used in the risk-adjusted models are listed in eTable 3
in Supplement 2. All analyses were performed using SAS Enterprise Guide, version 7.11 (SAS
Institute Inc).
The primary analysis compared the mean without-fail rate in the 1-year baseline period vs the
1-year active implementation period. We also compared the change in the without-fail rate from
baseline to 1 year between the PREVENT sites and the matched control sites to ameliorate the
potential association of temporal trends in care that may have confounded the assessment of the
intervention association within the cluster design.
The secondary analyses included a comparison of baseline vs active implementation for the
consolidated measure of quality, the 7 guideline-recommended processes of care, and 90-day
outcomes. The primary analyses were focused on the first TIA event per patient during the study
period (eg, a patient with a TIA event in both baseline and active implementation was only included
in the baseline period). We also conducted sensitivity analyses in which we included all TIA events (ie,
not restricted to the first TIA event) and excluded patients 90 years or older (because care for such
patients may appropriately not include all of the processes of care that are included in the without-
fail rate). The testing was 2 sided, with the threshold of statistical significance set at P < .05.
Power and Sample Size
The methods used for the sample size design and power calculation for this nonrandomized cluster
trial with matched controls have been reported.35 Briefly, the 6-site study was designed to provide
greater than 90% power to detect an improvement in the mean facility without-fail rate from 25%
during the baseline period to greater than 45% during the active implementation period. The goal for
the sample size was to recruit sites with at least 50 patients with TIA per year; however, based on the
original sample size calculations, power would be preserved with at least 30 patients with TIA per
year for an effect size of 20% increase in the mean facility without-fail rate. This study was not
powered to detect differences in patient outcomes (eg, mortality, recurrent events).
Results
The mean (SD) age of participants at baseline was 69.9 (11.2) years at PREVENT sites and 71.6 (11.3)
years at matched control sites. Most patients were male (95.1% [154 of 162] at the PREVENT sites and
94.6% [920 of 973] at the matched control sites at baseline).
The 6 PREVENT sites were geographically diverse, including sites in the West, Northeast,
Southeast, and Midwest. The annual TIA patient volume varied across sites, ranging from 13 to 43
patients. The sites varied in terms of the infrastructure to provide care for patients with TIA and to
improve quality of care. Five of the 6 teams were led by a neurologist (1 team was co-led by a facility-
based systems redesign specialist), and 1 team was led by an emergency medicine quality
management nurse. All sites had neurology attending staff coverage, but the neurology service
varied across sites in terms of size (the median neurology full-time equivalent [FTE] was 4.7;
interquartile range, 3.1-6.7), admitting service status (vs consulting service only), and teaching status
(neurology resident training program). All sites had an ED (the median ED FTE was 7.1; interquartile
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range, 6.1-8.9). All sites had pharmacists as team members. Although none of the sites had
preexisting teams or projects monitoring or improving TIA care, all teams had at least 1 member with
previous QI experience. The PREVENT sites and the matched control sites were similar in terms of
neurology and ED FTEs (eTable 4 in Supplement 2).
Table 1 lists the patient characteristics of the 6 PREVENT sites (during baseline and active
implementation periods) and the matched control sites, including CHA2DVAS2c (congestive heart
failure or left ventricular dysfunction, hypertension, age 75 years or older [doubled], diabetes, stroke
[doubled]–vascular disease, age 65 to 74 years, and sex category [female]),36 HAS-BLED
(hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile
international normalized ratio [if taking warfarin sodium], elderly [eg, age >65 years, frail condition],
drugs [eg, aspirin, nonsteroidal anti-inflammatory drugs]/alcohol concomitantly),37 and APACHE
(Acute Physiology and Chronic Health Evaluation)38 values. Most patients with TIA were admitted to
the hospital, but the hospital admission rate was higher in the PREVENT sites compared with the
matched control sites (77.2% [125 of 162 patients] vs 64.5% [628 of 973 patients], P = .002).
Comorbidities were common, including hypertension in 79.6% (129 of 162) of patients,
hyperlipidemia in 67.9% (110 of 162), and diabetes in 48.1% (78 of 162) (Table 1). The patient
characteristics were similar between patients cared for in the PREVENT sites and the matched
control sites (Table 1). Within the PREVENT sites, the characteristics of patients were similar during
the baseline and active implementation periods (Table 1).
Change in the Primary and Secondary Outcomes
Among the PREVENT sites, the mean without-fail rate improved from 36.7% (58 of 158 patients) at
baseline to 54.0% (95 of 176 patients) during the implementation period (odds ratio [OR] adjusted
for facility and wave, 2.15; 95% CI, 1.34-3.45; P = .002) (Table 2); eTable 5 in Supplement 2 lists
changes in individual facility performance). The improvement in the mean without-fail rate persisted
after adjustment for patient characteristics (adjusted OR, 2.10; 95% CI, 1.27-3.48; P = .004). The
mean without-fail rate improved 14.1% more at the PREVENT sites (36.7% [58 of 158 patients] to
54.0% [95 of 176 patients], an absolute improvement of 17.3%) than at the matched control sites
(38.6% [345 of 893 patients] to 41.8% [363 of 869 patients], an absolute improvement of 3.2%)
(P = .01) (Table 3 and Figure 2).
The mean (SD) consolidated measure of quality (secondary outcome) also improved at the
PREVENT sites, from 79.6% (20.1%) to 88.0% (15.9%) (P < .001). Similarly, the improvement in the
consolidated measure of quality was greater at the PREVENT sites (from 79.6% to 88.0%, an
absolute improvement of 8.4%) than at the matched control sites (from 80.4% to 82.6%, an
absolute improvement of 2.2%) (P = .01). At the PREVENT sites, the observed pass rates increased
for 6 of the 7 primary processes of care from baseline to active implementation; however, few of the
improvements were statistically significant after adjustment (Table 3).
At the PREVENT sites, the observed 90-day all-cause mortality rate decreased from 2.5% (4 of
162 patients) to 1.6% (3 of 189 patients), a decrement of −0.9%; at the matched control sites, the
observed 90-day mortality rate similarly declined from 2.3% (22 of 973 patients) to 1.7% (16 of 968
patients), a decrement of −0.6% (eTable 6 in Supplement 2). Similarly, the 90-day stroke rate, the
combined 90-day stroke or death rate, and the recurrent event rate decreased from the baseline
period to the implementation period; although the decrements were modestly higher for the
PREVENT sites than for the matched control sites for all-cause mortality, stroke, and stroke or death,
none of these differences were statistically significant (eTable 6 and eFigure 1 in Supplement 2).
Sensitivity Analysis
The results of the sensitivity analysis that included all patients with TIA (168 patients at baseline, 196
patients after active implementation) were identical to the results obtained in the main analysis,
which included patients with a first TIA during the study period (162 patients at baseline, 189 patients
after active implementation). The results of the sensitivity analyses that excluded patients 90 years
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Table 1. Baseline Patient Characteristics
Baseline patient characteristic
No. (%) P value















Admitted vs ED for index event
ED only 345 (35.5) 310 (32.0) 37 (22.8) 36 (19.0)
.002 .43
Admitted to the hospital 628 (64.5) 658 (68.0) 125 (77.2) 153 (81.0)
Weekday presentation 782 (80.4) 759 (78.4) 130 (80.2) 143 (75.7) >.99 .37
Left against medical advice 38 (3.9) 52 (5.4) 4 (2.5) 9 (4.8) .50 .40
Demographic characteristics
Age, y
Mean (SD) 71.7 (11.3) 71.4 (10.9) 69.9 (11.2) 68.8 (11.3) .06 .38
Median (IQR) 71.0 (65.0-80.0) 71.0 (65.0-78.0) 69.0 (63.0-76.0) 69.0 (61.0-75.0) .02 .52
Male sex 920 (94.6) 914 (94.4) 154 (95.1) 181 (95.8) >.99 .80
Race
White 770 (79.1) 727 (75.1) 116 (71.6) 124 (65.6)
.11 .65
Black 145 (14.9) 184 (19.0) 37 (22.8) 50 (26.5)
Asian 5 (0.5) 9 (0.9) 0 2 (1.1)
Other 4 (0.4) 8 (0.8) 1 (0.6) 1 (0.5)
Unknown 49 (5.0) 40 (4.1) 8 (4.9) 12 (6.3)
Hispanic ethnicity 45 (4.6) 58 (6.0) 18 (11.1) 16 (8.5) .002 .47
Medical history
TIA outpatient encounter in prior 30 da 56 (5.8) 38 (3.9) 7 (4.3) 11 (5.8) .58 .63
Stroke in prior 30 d 65 (6.7) 57 (5.9) 7 (4.3) 10 (5.3) .30 .81
Diabetes 404 (41.5) 411 (42.5) 78 (48.1) 78 (41.3) .12 .20
Atrial fibrillation 171 (17.6) 178 (18.4) 35 (21.6) 32 (16.9) .23 .28
Myocardial infarction 71 (7.3) 79 (8.2) 14 (8.6) 11 (5.8) .52 .41
Congestive heart failure 165 (17.0) 164 (16.9) 22 (13.6) 21 (11.1) .36 .52
Carotid endarterectomy or stent 11 (1.1) 6 (0.6) 1 (0.6) 0 >.99 .46
Chronic obstructive pulmonary disease 207 (21.3) 202 (20.9) 27 (16.7) 36 (19.0) .21 .58
Peripheral arterial disease 163 (16.8) 153 (15.8) 20 (12.3) 29 (15.3) .17 .44
Dementia 81 (8.3) 63 (6.5) 16 (9.9) 12 (6.3) .54 .24
Chronic kidney disease 160 (16.4) 175 (18.1) 29 (17.9) 27 (14.3) .65 .38
Dialysis 13 (1.3) 21 (2.2) 6 (3.7) 1 (0.5) .04 .05
Cancer 123 (12.6) 100 (10.3) 15 (9.3) 21 (11.1) .25 .60
Hypertension 716 (73.6) 746 (77.1) 129 (79.6) 152 (80.4) .12 .89
Hyperlipidemia 584 (60.0) 610 (63.0) 110 (67.9) 120 (63.5) .07 .43
Speech deficit 44 (4.5) 57 (5.9) 13 (8.0) 12 (6.3) .08 .68
Motor deficit, hemiplegia 128 (13.2) 163 (16.8) 25 (15.4) 40 (21.2) .46 .21
Sleep apnea 177 (18.2) 237 (24.5) 34 (21.0) 44 (23.3) .39 .70
Alcohol dependence 72 (7.4) 77 (8.0) 14 (8.6) 21 (11.1) .63 .48
Depression 209 (21.5) 229 (23.7) 45 (27.8) 42 (22.2) .08 .27
History of venous thromboembolism 30 (3.1) 38 (3.9) 12 (7.4) 7 (3.7) .01 .16
Intracranial hemorrhage 57 (5.9) 52 (5.4) 13 (8.0) 10 (5.3) .29 .39
Gastrointestinal bleeding 7 (0.7) 5 (0.5) 2 (1.2) 1 (0.5) .62 .60
Migraine 25 (2.6) 28 (2.9) 8 (4.9) 9 (4.8) .12 >.99
Medications before index event
Antihypertensives 818 (84.1) 810 (83.7) 142 (87.7) 160 (84.7) .29 .44
Statin 785 (80.7) 808 (83.5) 135 (83.3) 169 (89.4) .45 .12
Aspirin 733 (75.3) 687 (71.0) 132 (81.5) 149 (78.8) .09 .59
Warfarin sodium 125 (12.8) 86 (8.9) 11 (6.8) 17 (9.0) .03 .55
CHA2DVAS2c, mean (SD)b 3.25 (1.47) 3.26 (1.49) 3.31 (1.39) 3.11 (1.33) .62 .15
(continued)
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or older (155 patients at baseline, 182 patients after active implementation) were likewise similar to
the main results.
Discussion
These results demonstrate that a multifaceted QI intervention was associated with improved quality
of TIA care across diverse hospitals and clinical teams; specifically, we observed a net improvement
Table 1. Baseline Patient Characteristics (continued)
Baseline patient characteristic
No. (%) P value














HAS-BLED, mean (SD)c 2.23 (1.03) 2.24 (1.08) 2.20 (1.09) 2.06 (1.02) .77 .22
Charlson Comorbidity Index score
Mean (SD) 2.9 (2.7) 2.9 (2.7) 2.8 (2.8) 2.7 (2.8) .75 .59
Median (IQR) 2.0 (1.0-4.0) 3.0 (2.0-4.0) 2.0 (0.0-4.0) 2.0 (0.0-4.0) .51 .60
Smoker 265 (27.2) 259 (26.8) 44 (27.2) 61 (32.3) >.99 .35
Palliative care, hospice 44 (4.5) 31 (3.2) 3 (1.9) 3 (1.6) .14 >.99
Present on admission
Concomitant myocardial infarction 23 (2.4) 24 (2.5) 8 (4.9) 5 (2.6) .07 .27
Concomitant congestive heart failure 15 (1.5) 19 (2.0) 4 (2.5) 1 (0.5) .33 .19
Laboratory and vital signs
APACHEd
Mean (SD) 9.5 (6.7) 10.2 (6.9) 10.2 (7.4) 9.2 (6.1) .25 .17
Median (IQR) 9.0 (4.0-14.0) 9.0 (5.0-14.0) 9.0 (5.0-14.0) 9.0 (4.0-12.0) .53 .57
First systolic blood pressure, mm Hg
Mean (SD) 147.7 (25.8) 148.5 (25.8) 145.3 (24.1) 142.8 (25.2) .27 .34
Median (IQR) 147.0 (129.0-165.0) 148.0 (130.0-164.0) 144.0 (128.0-162.0) 142.0 (125.0-159.0) .24 .39
First diastolic blood pressure, mm Hg
Mean (SD) 80.3 (13.1) 81.2 (14.4) 81.0 (14.6) 80.2 (14.4) .53 .62
Median (IQR) 80.0 (71.0-89.0) 81.0 (71.0-90.0) 80.0 (72.0-90.0) 79.0 (71.0-90.0) .85 .79
Average systolic blood pressure 90 d after
discharge, mm Hg
Mean (SD) 131.4 (16.4) 131.2 (15.8) 130.3 (15.6) 127.5 (14.1) .49 .10
Median (IQR) 130.4 (120.0-141.0) 130.0 (121.3-139.5) 130.0 (120.0-138.9) 126.6 (118.0-136.3) .57 .09
Average diastolic blood pressure 90 d after
discharge, mm Hg
Mean (SD) 74.5 (9.3) 73.7 (9.8) 74.6 (9.3) 73.1 (9.5) .93 .17
Median (IQR) 74.5 (68.7-80.0) 74.0 (67.0-80.0) 75.0 (69.0-80.0) 73.0 (67.0-80.0) .85 .21
Health care use
Any inpatient admission in year before
index event
303 (31.1) 280 (28.9) 55 (34.0) 43 (22.8) .47 .02
Any ED visit in year before index event 598 (61.5) 587 (60.6) 89 (54.9) 104 (55.0) .12 >.99
Primary care visit in 90 d after discharge 775 (79.7) 793 (81.9) 140 (86.4) 155 (82.0) .05 .31
Neurology visit in 90 d after discharge 379 (39.0) 411 (42.5) 73 (45.1) 82 (43.4) .14 .83
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; CHA2DVAS2c,
congestive heart failure or left ventricular dysfunction, hypertension, age 75 years or
older (doubled), diabetes, stroke (doubled)–vascular disease, age 65 to 74 years, and sex
category (female); ED, emergency department; HAS-BLED, hypertension, abnormal
renal/liver function, stroke, bleeding history or predisposition, labile international
normalized ratio (if taking warfarin sodium), elderly (eg, age >65 years, frail condition),
drugs (eg, aspirin, nonsteroidal anti-inflammatory drugs)/alcohol concomitantly; IQR,
interquartile range; TIA, transient ischemic attack.
a Patients were included in this cohort if they had a TIA event (defined as an ED visit or
inpatient admission for TIA); outpatient visits were not used to identify the index TIA
event. The first TIA ED visit or inpatient admission during the study period was
classified as the index event. Some of the patients in the cohort had an outpatient
encounter (eg, primary care visit) in the 30 days before the index TIA.
b CHA2DVAS2c is a score that describes the risk of thromboembolism among patients
with atrial fibrillation. Higher scores indicate greater risk of thromboembolism.36
c HAS-BLED refers to a score that describes the risk of bleeding among patients who are
anticoagulated. Higher scores indicate greater risk of bleeding.37
d APACHE scoring system is a measure of physiological illness and has been shown to
predict mortality risk among acutely ill patients. Higher scores indicate greater
physiological illness.38
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of 14.1% at PREVENT sites compared with matched control sites. Our results contribute to the
growing literature demonstrating that improvements in cerebrovascular disease quality of care are
achievable with complex interventions that are implemented by clinical staff who are committed to
engaging in QI.39 Previous studies23,39,40 seeking to improve quality and timeliness of TIA care have
varied in terms of the targeted population (stroke, TIA), details of the QI intervention, and targeted
processes of care; however, common intervention components have included audit and feedback in
combination with external facilitation to support clinical teams, staff and patient education,
checklists or clinical pathways, and electronic tools. Despite the heterogeneity in design, the QI
interventions in general have successfully improved processes of care. For example, Machline-
Carrion et al39 implemented a QI program seeking to improve care for patients with ischemic stroke
and TIA and found that the all-or-none measure of quality was higher among patients in the
intervention hospitals (49.2%) than in the control hospitals (25.2%) (OR, 2.59; 95% CI, 1.22-5.53;
P = .01), a difference of 24.0%. Although the study by Machline-Carrion et al39 differed substantially
from the present study (eg, included patients with stroke and focused on acute stroke processes of
care like thrombolytics), the finding that the all-or-none measure varied between 25.2% and 49.2%,
whereas the consolidated measure of quality varied between 77.8% and 85.3%, is similar to the
present study, where the without-fail rate varied between 36.7% and 54.0% and the consolidated
measure of quality varied between 79.6% and 88.0%. Although a facility may be satisfied with an
88.0% pass rate on a consolidated measure of quality, at the patient-level, only 54.0% of patients at
that facility received all of the care for which they were eligible. In a study30 of patients with TIA and
ischemic stroke, without-fail care was associated with 31.2% lower odds of 1-year mortality (adjusted
OR, 0.69; 95% CI, 0.55-0.87), providing evidence to support the association between quality and
outcome. Health care systems should consider including TIA in their existing stroke quality
measurement programs and should consider evaluating progress against all-or-none quality
measures.
The without-fail rate can be a difficult measure to improve. Patients pass the without-fail rate if
they received all of the processes of care for which they were eligible (eFigure 2 in Supplement 2
shows the calculation of the without-fail rate). Consider 2 hypothetical facilities, each with a without-
fail rate of 40%. In 1 case, the quality problems span several processes of care (eFigure 2 in
Supplement 2). At this hypothetical facility, the QI team would have had to improve a broad range of
processes to ensure that all patients received all of the care for which they were eligible. This scenario
Table 2. Effectiveness Comparing the Baseline Period With the Implementation Period at the PREVENT Sitesa
Guideline-recommended
process of care
Baseline (n = 162) Implementation (n = 189) Partially adjustedb Fully adjustedc
Eligible, No. Pass rate, No. (%) Eligible, No. Pass rate, No. (%) OR (95% CI) P value OR (95% CI) P value
Anticoagulation for atrial
fibrillation
30 19 (63.3) 27 27 (100) 28.68 (1.79-458.94) .02 22.54 (1.72-294.94) .02
Antithrombotic use 142 139 (97.9) 165 159 (96.4) 0.71 (0.17-3.01) .64 0.50 (0.08-2.95) .44
Brain imaging 158 148 (93.7) 176 173 (98.3) 3.69 (0.97-14.07) .06 3.95 (1.01-15.37) .048
Carotid artery imaging 155 119 (76.8) 173 147 (85.0) 1.92 (1.06-3.47) .03 1.99 (1.02-3.91) .04
High- or moderate-potency
statin therapy
136 92 (67.6) 152 124 (81.6) 1.99 (1.13-3.51) .02 2.02 (0.98-4.14) .06
Hypertension control 120 93 (77.5) 124 102 (82.3) 1.28 (0.67-2.45) .45 1.15 (0.57-2.35) .69
Neurological consultation 155 103 (66.5) 173 138 (79.8) 2.15 (1.25-3.71) .006 2.09 (1.19-3.66) .01
Without-fail rate 158 58 (36.7) 176 95 (54.0) 2.15 (1.34-3.45) .002 2.10 (1.27-3.48) .004
Abbreviations: OR, odds ratio; PREVENT, Protocol-Guided Rapid Evaluation of Veterans
Experiencing New Transient Neurological Symptoms.
a The PREVENT sites refer to the 6 participating sites that engaged in active quality
improvement by implementing the intervention; 158 baseline and 176 intervention
patients were eligible for at least one process of care and were included in the quality-
of-care analyses.
b The partially adjusted results were obtained from a model that included a random-
effects size analysis for facility and fixed effects for wave.
c The fully adjusted results were obtained from a model that included a random-effects
size analysis for facility and fixed effects for wave and also included patient
characteristics associated with each process of care measure, the consolidated
measure of quality, or the without-fail rate (eTable 3 in Supplement 2 lists the specific
variables included in each model).
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was the case at 1 PREVENT site, where the QI team implemented comprehensive systems of care to
address the multiple areas in which quality gaps were evident, including routine monitoring of quality
data, prospective real-time interventions to address gaps in care, implementation of new order sets,
and facility-wide education programs. It took time to implement these activities; hence, the without-
fail rate improved during the 1-year implementation period (from 16% to 35%), but did not achieve
the goal of at least 50% that the team established for themselves at the beginning of the project.
However, we hypothesize that the without-fail rate will continue to improve at this facility in the
postimplementation period given that TIA quality of care management has been imbedded in routine
operations. Consider a second hypothetical facility at which the without-fail rate is 40% but where
patients with TIA received all of the measures for which they were eligible except for problems in 1
process (eFigure 2 in Supplement 2). At this second facility, the QI team could focus on a single
process of care. This scenario was the case at another PREVENT site, which achieved substantial
improvements in the without-fail rate (from 39% to 60%) by improving the prescription of high- or
moderate-potency statin therapy for eligible patients. However, given that the team at this site did
not implement any facility-wide modifications in procedures, nor did they establish routines to
monitor quality of care data, we hypothesize that their quality will diminish during the
postimplementation period.
Strengths and Limitations
A methodological strength of the present study was the augmentation of the cluster design with the
use of the matched control comparison. A limitation of nonrandomized cluster design in cases where
either the baseline period is short or the sample size during the baseline period is insufficient to allow
for segmentation of the baseline period into distinct subperiods can be the potential for confounding
by temporal trends.41,42 The improvement observed at the matched control sites suggests that the
quality of care improved over time and confirms the importance of evaluating care at the matched
control sites.
The PREVENT QI program is an example of a learning health care system in action.15 Learning
health care systems develop QI programs that are data driven, meet the needs of stakeholders, and
dynamically adapt to changes in performance and context. For example, 3 processes of care with the
greatest opportunities for improvement for the greatest number of eligible patients at baseline
included neurological consultation, hypertension control, and the use of high- or moderate-potency
statin therapy. Although the without-fail rate included 7 processes of care, the 3 processes listed
above were common QI targets at the PREVENT sites, demonstrating how QI programs can be data
driven and adaptable. Both hypertension control and the use of high- or moderate-potency statin
therapy are part of the scope of practice of existing VA pharmacy staff; all of the PREVENT sites
























The primary outcome was the without-fail rate, which
is calculated as the proportion of veterans with
transient ischemic attack (TIA) at a specific facility who
received all 7 guideline-recommended processes of
care for which they were eligible (ie, anticoagulation
for atrial fibrillation, antithrombotic use, brain imaging,
carotid artery imaging, high- or moderate-potency
statin therapy, hypertension control, and neurological
consultation). PREVENT indicates Protocol-Guided
Rapid Evaluation of Veterans Experiencing New
Transient Neurological Symptoms.
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engaged pharmacists on their QI teams, providing an example of how a QI project can leverage local
resources.43 Another common approach was to increase the proportion of patients with TIA who
were admitted given the observation that patients who were discharged from the ED were less likely
to receive guideline-recommended processes of care, providing an example of using data
infrastructure to identify strategies for improvement.12
This study has some limitations. First, the primary limitation is that the PREVENT program was
implemented only within VA facilities, which may limit generalizability; future research should evaluate
its effectiveness when implemented at non-VA sites, where the health care infrastructure (eg, elec-
tronic health record and QI culture) may vary. Moreover, given that the sites were selected on the basis
of gaps in quality of care at baseline, the results may not generalize to high-performing hospitals. Sec-
ond, there may be some diagnostic uncertainty when making a diagnosis of TIA.44 However, given that
miscoding is likely to exist across all of the sites, it is unlikely that this limitation altered the assessment
of the intervention association. Third, because the intervention included multiple components, we are
unable to isolate and estimate the unique associations of each specific element. Fourth, neither site
selection nor allocation to waves was randomized. Therefore, the possibility of selection bias cannot be
eliminated; in addition, although the matched control sites were similar to the PREVENT sites in several
key aspects, they were not matched on the unmeasurable characteristics associated with motivation to
improve TIA care. The results should be considered as associations and not causal relationships. Fifth,
the anticoagulation for atrial fibrillation measure evaluated whether anticoagulation was prescribed for
patients with a diagnosis of atrial fibrillation (preexisting or new diagnosis); the measure did not evalu-
ate whether patients received screening for atrial fibrillation. Sixth, we cannot explain why modest dec-
rements in pass rates for antithrombotic use were observed both at the PREVENT sites and the
matched control sites (Table 3); future studies should explore potential mechanisms of this finding.
Seventh, although a 6-site sample provided adequate power for the detection of changes in processes
of care, the study was not powered to detect changes in patient outcomes. Future studies might in-
clude a larger number of facilities and more patients to provide power to detect differences in patient
outcomes, such as recurrent stroke or mortality. Research is ongoing to examine the sustainability of
TIA QI at the PREVENT sites.
Conclusions
We believe that the PREVENT sites achieved remarkable improvements in quality of care despite
heterogeneity in their baseline quality of care and team composition. Other health care systems
interested in improving TIA quality of care may consider making similar interventions available to
their clinical teams, which include readily available implementation tools, professional educational
materials, an audit and feedback mechanism, external facilitation support, and virtual collaborative
learning. The VA was the first US federal agency to support the core values of the learning health care
system, which has been recognized as an exemplary organization that harnesses the power of data
to improve the health of the populations it serves.45 Based on the observed improvements in quality
of care, the PREVENT QI program was deployed nationwide across the VA health care system in 2019.
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